Beranda › Tumor Wilms › Distrik Columbia
Uji klinis Tumor Wilms di Distrik Columbia
7 studi untuk Tumor Wilms mencari peserta di lokasi di Distrik Columbia.
Kota di Distrik Columbia
Teks studi resmi (Bahasa Inggris)
Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor
- Children's National Medical Center, Washington D.C.
Menerima pesertaFase 2
Usia 12 hingga 39 · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT04616560Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Children's National Medical Center, Washington D.C.
Menerima pesertaFase 1/2
12 Months – 30 Years · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT04851119A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
- MedStar Georgetown University Hospital, Washington D.C.
- Children's National Medical Center, Washington D.C.
Menerima pesertaFase 2
Hingga usia 30 · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT04322318Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
- Children's National Hospital, Washington D.C.
- Childrens National Hospital, Washington D.C.
Menerima pesertaFase 1
Usia 1 hingga 23 · Semua jenis kelamin · Diperbarui 13 Agu 2026 · NCT07172958Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
- Children's National Medical Center, Washington D.C.
Menerima pesertaFase 1/2
12 Months – 30 Years · Semua jenis kelamin · Diperbarui 19 Mei 2026 · NCT04901702A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
- Children's National Hospital (Data Collection Only), Washington D.C.
Menerima pesertaFase 2
12 Months · Semua jenis kelamin · Diperbarui 6 Mei 2026 · NCT05985161A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
- Children's National Medical Center, Washington D.C.
Menerima pesertaFase 2
18 Months – 40 Years · Semua jenis kelamin · Diperbarui 12 Agu 2025 · NCT05135975Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.